drugset
drugset / Trial / NCT07138755

The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients

NCT07138755 ↗

Phase 2 Recruiting 35 enrolled The Third Xiangya Hospital of Central South University
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients

Timeline

Start
2025-08-29
Primary completion
2028-12
Completion
2030-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 5 unknown Intravenous
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject Paclitaxel Small molecule 135 mg/m2 Intravenous
Subject Paclitaxel Small molecule 175 mg/m2 Intravenous
Subject Paclitaxel liposome Unknown 135 mg/m2 Intravenous
Subject Paclitaxel liposome Unknown 175 mg/m2 Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous
Subject Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

non-small cell lung carcinoma